These findings are supported by a great number of scientific data of the effectiveness of pan-HDAC inhibition in tumor growth inhibition on a huge number of tumor models including: pancreatic, esophageal squamous cell carcinoma (ESCC), multiple myeloma, prostate carcinoma, gastric cancer, leukemia, breast, liver cancer, ovarian cancer, non-Hodgkin lymphoma, and neuroblastoma (Table 3). Here, HDAC9 is linked to neoplasm.